Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03739684 · ClinicalTrials.gov registry record · Phase 3
Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
A Phase 3 study, sponsored by Progenics Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 208
- Enrollment target
NCT03739684 is a Phase 3 study that has completed, run by Progenics Pharmaceuticals. The registered enrollment target is 208 participants.
The verdict
NCT03739684, a Phase 3 study, has completed, sponsored by Progenics Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 208 participants
- Enrollment target
Study Summary
This study evaluates the diagnostic performance and safety of 18F-DCFPyL (PyL) PET/CT imaging in patients with suspected recurrence of prostate cancer who have negative or equivocal findings on conventional imaging.
Interventions
- DRUG 18F-DCFPyL
- DIAGNOSTIC_TEST PET/CT Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2018-11-27 |
| Est. Completion | 2019-08-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03739684
The ClinicalTrials.gov registry entry for NCT03739684 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 208 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Progenics Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 18F-DCFPyL is the first listed.
NCT03739684 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03739684 about?
NCT03739684 is a clinical study titled "Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer". This study evaluates the diagnostic performance and safety of 18F-DCFPyL (PyL) PET/CT imaging in patients with suspected recurrence of prostate cancer who have negative or equivocal findings on conventional imaging.
What is the current status of trial NCT03739684?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 208 participants. The study started on 2018-11-27. Estimated completion is 2019-08-29.
What interventions are being tested in trial NCT03739684?
The interventions under investigation include: 18F-DCFPyL (DRUG), PET/CT Imaging (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03739684?
This trial is sponsored by Progenics Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.